Progress in Molecular Biology and Translational Science
Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A
Series: Progress in Molecular Biology and Translational Science; 162;
- Publisher's listprice EUR 122.00
-
50 599 Ft (48 190 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 5 060 Ft off)
- Discounted price 45 540 Ft (43 371 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
50 599 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 23 March 2019
- ISBN 9780128177389
- Binding Hardback
- No. of pages418 pages
- Size 229x152 mm
- Weight 840 g
- Language English 0
Categories
Long description:
Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A, Volume 162 in the Progress in Molecular Biology and Translational Science series provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include Glycan-based Biomarkers for Diagnosis of Cancers and Other Diseases: Past, Present and Future, Desialylation in Diseases and its Application in Diagnostic and Therapeutic Development, Proteoglycans as Miscommunication Biomarkers for Cancer Diagnosis, Fucosylation in Cancer Biology and Its Clinical Applications, Retrospective Analysis of Glycan-Related Biomarkers Based on Clinical Laboratory Data in Two Medical Centers, and many related topics.
MoreTable of Contents:
1. Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future
Minghui Hu, Ying Lan, Alexander Lu, Xuexiao Ma and Lijuan Zhang
2. Desialylation in physiological and pathological processes: New target for diagnostic and therapeutic development
Mohui Wei and Peng George Wang
3. Proteoglycans as miscommunication biomarkers for cancer diagnosis
Lingling Xu, Limin Tang and Lijuan Zhang
4. Fucosylation in cancer biology and its clinical applications
Ming Shan, Dandan Yang, Huaiqian Dou and Lijuan Zhang
5. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection
Yang Tang, Yidi Cui, Shufeng Zhang and Lijuan Zhang
6. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past six years
Meng Zhang, Huaiqian Dou, Dandan Yang, Ming Shan, Xiulian Li, Cui Hao, Yiran Zhang, Pengjiao Zeng, Yanli He, Yong Liu, Jing Fu, Wei Wang, Minghui Hu, Hui Li, Qingwu Tian, Shuhe Lei and Lijuan Zhang
7. Serum SCCA levels in patients suffering cancers or other diseases
Dandan Yang, Jun Wang and Lijuan Zhang
8. Increased serum CA724 levels in patients suffering gout vs cancers
Yiran Zhang, Meng Zhang, Xueshan Bai, Changgui Li and Lijuan Zhang
9. Serum CA50 levels in patients with cancers and other diseases
Ming Shan, Qingwu Tian and Lijuan Zhang
10. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases
Yanli He, Haijun Lu and Lijuan Zhang
11. Serum CEA levels in 49 different types of cancer and noncancer diseases
Cui Hao, Guoqing Zhang and Lijuan Zhang
12. CA242 as a biomarker for pancreatic cancer and other diseases
Huaiqian Dou, Guirong Sun, and Lijuan Zhang
13. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers
Meng Zhang, Yiran Zhang, Jing Fu and Lijuan Zhang
14. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases
Pengjiao Zeng, Hui Li, Yulong Chen, Haitao Pei and Lijuan Zhang
15. Serum CA153 as biomarker for cancer and non-cancer diseases
Xiulian Li, Yan Xu and Lijuan Zhang
16. Fasting blood glucose levels in patients with different types of diseases
Qinghua Zhang, Gang Zhao, Nailong Yang and Lijuan Zhang
17. HbA1c: High in acute cerebral infarction and low in brain trauma
Zhifeng Jiang, Jigang Wang, Peng Zhao, Lijuan Zhang and Yunliang Guo
18. Glycated albumin level is significantly decreased in patients suffering nephrotic syndrome
Zhe Wang, Guangqun Xing, Lijuan Zhang
19. Glycated serum proteins: High in pancreatic cancer and low in preeclampsia
Xueling Wang, Rui Zhang, Lijuan Zhang and Zibin Tian
20. The serum SA levels are significantly increased in sepsis but decreased in cirrhosis
Xiaodan Huang, Qin Yao, Lijuan Zhang and Zibin Tian
21. Serum ?-L-fucosidase activities are significantly increased in patients with preeclampsia
Meng Zhang, Lin Wang, Haiping Zhang, Juan Cong and Lijuan Zhang
22. Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy
Limin Tang, Meng Zhang, Xiulian Li and Lijuan Zhang
23. Serum PSA levels in patients with prostate cancer and other 33 different types of diseases
Yanyun Gao, Meng Zhang, Xiulian Li, Pengjiao Zeng, Peitao Wang and Lijuan Zhang
